Marco Finocchietti, Maria Lucia Marino, Alessandro C Rosa, Arianna Bellini, Lucia Masiero, Massimo Cardillo, Marco Massari, Stefania Spila Alegiani, Silvia Pierobon, Eliana Ferroni, Martina Zanforlini, Olivia Leoni, Stefano Ledda, Donatella Garau, Marina Davoli, Antonio Addis, Valeria Belleudi
PURPOSE: This study evaluates the use, benefit-risk profile, and economic impact of generic immunosuppressants (tacrolimus-TAC, cyclosporine-CsA, and mycophenolate-MYC) in kidney and liver transplant recipients compared to brand-name drugs. PATIENTS AND METHODS: A retrospective multicentre observational study, involving four Italian regions, was conducted based on the national transplant Information system and regional healthcare claims data. The analysis focused on incident patients who received kidney and liver transplants between 2013 and 2019 and evaluated the use of generic of CsA, TAC, and MYC during the 30-day period following discharge...
2024: Drug Design, Development and Therapy